Drilldown: Medicines
Medicines > classes 
:
Benzodiazepine or
[[:Category:Angiotensin_receptor_blockers|Angiotensin receptor blocker (ARB)]]
:
Benzodiazepine or
[[:Category:Angiotensin_receptor_blockers|Angiotensin receptor blocker (ARB)]] Use the filters below to narrow your results.
generic:
Alprazolam (1) ·
Bromazepam (1) ·
Chlordiazepoxide (1) ·
Clobazam (1) ·
Clonazolam (1) ·
Clorazepate (1) ·
Diclazepam (1) ·
Estazolam (1) ·
Flualprazolam (1) ·
Flubromazepam (1) ·
Flubromazolam (1) ·
Flunitrazepam (1) ·
Flunitrazolam (1) ·
Flurazepam (1) ·
Irbesartan (1) ·
Lormetazepam (1) ·
Losartan (1) ·
Midazolam (1) ·
Nifoxipam (1) ·
Nitrazepam (1) ·
Olmesartan (medoxomil) (1) ·
Oxazepam (1) ·
Pyrazolam (1) ·
Quazepam (1) ·
Telmisartan (1) ·
Temazepam (1) ·
Triazolam (1) ·
Valsartan (1)
brand:
None (9) ·
Avapro (1) ·
Benicar (1) ·
Cozaar (1) ·
Dalmane (1) ·
Diovan; Entresto (in fixed-dose combination with sacubitril) (1) ·
Doral (1) ·
Halcion (1) ·
Lexotan (1) ·
Librium (1) ·
Micardis (1) ·
Mogadon (1) ·
Onfi (1) ·
ProSom (1) ·
Restoril (1) ·
Rohypnol (1) ·
Serax (1) ·
Tranxene (1) ·
Versed (1) ·
Xanax (1)
classes: (Click arrow to add another value)
mechanism:
None (1) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) ·
GABAA positive allosteric modulator (18) ·
GABAA positive allosteric modulator; low sedation (1) ·
GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) ·
GABAA positive allosteric modulator; very long half-life (1) ·
'"`UNIQ--vote-000000B6-QINU`"' Active metabolite EXP3174 is ~10-40-fold more potent than the parent and accounts for most of the antihypertensive effect; CYP2C9 polymorphism affects conversion'"`UNIQ--ref-000000B7-QINU`"'. (1) ·
'"`UNIQ--vote-000004C8-QINU`"' Largely hepatically cleared (~80% biliary); no active metabolite. Sacubitril-valsartan (Entresto) combines an ARB with neprilysin inhibition for HFrEF and was a notable advance over the ARB-alone trial (PARADIGM-HF, 2014)'"`UNIQ--ref-000004C9-QINU`"'. (1) ·
'"`UNIQ--vote-0000083E-QINU`"' CYP2C9 substrate; no clinically active metabolites. The IDNT trial established renoprotection in diabetic nephropathy independent of BP lowering, contributing to the ARB class indication in T2DM with proteinuria'"`UNIQ--ref-0000083F-QINU`"'. (1) ·
'"`UNIQ--vote-00000AEA-QINU`"' The 24-hour half-life supports once-daily dosing with consistent overnight BP control. Largely hepatically cleared (~98% biliary); no significant renal clearance dependence'"`UNIQ--ref-00000AEB-QINU`"'. (1)
uses:
None (22) ·
'"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1) ·
'"`UNIQ--vote-000000B8-QINU`"', '"`UNIQ--vote-000000B9-QINU`"', '"`UNIQ--vote-000000BA-QINU`"', '"`UNIQ--vote-000000BB-QINU`"' (1) ·
'"`UNIQ--vote-000004CA-QINU`"', '"`UNIQ--vote-000004CB-QINU`"', '"`UNIQ--vote-000004CC-QINU`"' (1) ·
'"`UNIQ--vote-0000056B-QINU`"' (1) ·
'"`UNIQ--vote-00000840-QINU`"', '"`UNIQ--vote-00000841-QINU`"' (1) ·
'"`UNIQ--vote-00000AEC-QINU`"', '"`UNIQ--vote-00000AED-QINU`"' (1)
starting dose:
None (22) ·
0.25 mg (1) ·
150 mg PO once daily; titrate to 300 mg if needed (1) ·
20 mg PO once daily; titrate to 40 mg/d after 2 weeks if needed (1) ·
40 mg PO once daily; titrate to 80 mg (1) ·
50 mg PO daily (25 mg in volume depletion or hepatic impairment) (1) ·
80-160 mg PO once daily (40 mg BID in HFrEF, titrating up to 160 mg BID) (1)
preparations:
None (22) ·
0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) ·
20, 40, 80 mg tablets (1) ·
25 mg, 50 mg, 100 mg tablets (1) ·
40, 80, 160, 320 mg tablets; oral suspension (1) ·
5, 20, 40 mg tablets (1) ·
75, 150, 300 mg tablets (1)
fda max:
onset:
halflife:
None (22) ·
11-13 h (immediate-release); 11-16 h (extended-release) (1) ·
11-15 hours'"`UNIQ--ref-00000842-QINU`"' (1) ·
2 hours (parent); 6-9 hours for active carboxylic acid metabolite EXP3174'"`UNIQ--ref-000000BC-QINU`"' (1) ·
~13 hours'"`UNIQ--ref-0000056C-QINU`"' (1) ·
~24 hours (longest of the ARB class; suits patients with morning BP surge)'"`UNIQ--ref-00000AEE-QINU`"' (1) ·
~6 hours'"`UNIQ--ref-000004CD-QINU`"' (1)
bioavailability:
None (22) ·
42-58% (oral; dose-dependent)'"`UNIQ--ref-00000AEF-QINU`"' (1) ·
60-80% (oral; not significantly affected by food)'"`UNIQ--ref-00000843-QINU`"' (1) ·
80-90% oral (1) ·
~25% (oral; food reduces absorption ~40%)'"`UNIQ--ref-000004CE-QINU`"' (1) ·
~26% (oral; prodrug hydrolyzed by intestinal esterases to active olmesartan; not affected by food)'"`UNIQ--ref-0000056D-QINU`"' (1) ·
~33% (extensive first-pass via CYP2C9 and CYP3A4)'"`UNIQ--ref-000000BD-QINU`"' (1)
pregnancy:
None (22) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-000000BE-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-000004CF-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-0000056E-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-00000844-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-00000AF0-QINU`"' (1) ·
Category D'"`UNIQ--ref-0000006C-QINU`"' (1)
Showing below up to 28 results in range #1 to #28.